VTGN
Vistagen Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.19
+11.49%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.17
From 52W high−96.18%
Volume1.02M
Market cap$8.31M
P/E (TTM)—
P/S (TTM)3.3x
Div yield—
Key dataNov 4, 2026
Open
$0.17
From 52W high
−96.18%
Volume
1.02M
Market cap
$8.31M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
34.0
MomentumView details →
1D Return
+11.49%
YTD Return
−73.68%
SummaryUpdated Jun 1, 2026
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company founded in 1998 and headquartered in South San Francisco, California. The company specializes in developing novel treatments for central nervous system disorders, particularly anxiety and depression. VistaGen went public in 2011 and has built a pipeline of innovative nasal spray therapies that target brain neurocircuitry through a unique nose-to-brain delivery mechanism. The company is currently advancing multiple drug candidates through clinical trials, with its lead program for social anxiety disorder in Phase III development.
Similar companies
Latest newsMore news →
Vistagen Therapeutics, Inc. selected GATC Health Corp. to apply predictive AI to Vistagen Therapeutics, Inc.’s lead clinical-stage drug development programs, combining Vistagen Therapeutics, Inc.’s neuroscience expertise and datasets with GATC Health Corp.’s predictive modeling capabilities to inform protocol development and resource allocation.15d agoVistagen presented positive exploratory data at Psych Congress 2026 in New Orleans supporting the potential of its intranasal pherine candidate fasedienol in very severe social anxiety disorder.42d agoVistagen announced preliminary positive data from the open-label extension portion of the PALISADE-4 Phase 3 study of fasedienol nasal spray for the acute treatment of social anxiety disorder, showing the drug was well-tolerated with no new drug-related safety findings after as-needed use for up to 12 months.43d ago